Report Reveals New Drugs Reach Patients Sooner in the U.S. than in Europe

June 2011 Monthly Message

Smithsonian Magazine Showcases Drug Development Process
Federal Update: What's Going on in Washington
Report Reveals New Drugs Reach Patients Sooner in the U.S. than in Europe
Join us for the 2011 Udall Awards Dinner
PAN CEO Amy Comstock Rick Featured on Comcast Newsmakers
Parkinson's in the Media

-----

A new study published in Health Affairs and funded by the Friends of Cancer Research shows that approval rates of oncology drug products are higher and time for review is lower in the United States than in Europe.  We found this study interesting for two reasons: 1) it was an unexpected outcome; and 2) because while the results are limited to cancer treatment, they remind us to question assumptions we've made in other areas of healthcare research.  This study, coupled with a letter from FDA Commissioner Margaret Hamburg in The Washington Post earlier this year (which the study references) challenges preconceived notions in the area of global competitiveness as it relates to drug development and the regulatory environment.  Click here to read the study and its results.